X-ray-activated nanoparticles release cancer-killing light deeper into tissue

Luminescence of photodynamic particles with X-ray activation--Courtesy of the Journal of Biomedical Nanotechnology

Researchers at the University of Texas at Arlington found that nanoparticles they were studying for radiation detection in the security arena could produce a toxic byproduct able to damage cancer cells.

In what is called a photodynamic therapy method, which delivers light to a tumor as a cancer treatment, UT physicist Wei Chen found that copper-cysteamine, or Cu-Cy, nanoparticles lost energy over time when combined with X-ray exposure, which led to slower growth of nearby cancer cells. Chen published the research in the Journal of Biomedical Nanotechnology, to be released in August.

Often photodynamic therapy is induced with a near-infrared laser, but Chen found that X-ray exposure allowed for deeper tissue penetration. And the Cu-Cy nanoparticles can work on their own without other photosensitizers, like other luminescent particles used previously for this purpose.

The team tested the method on human breast and prostate cancer cells and found in one case that a tumor stayed "virtually the same size" over 13 days while an untreated tumor grew to about three times its original size.

"This new idea is simpler and better than previous photodynamic therapy methods," Chen said in a statement. "You don't need many steps. This material alone can do the job. It is the most promising thing we have found in these cancer studies and we've been looking at this for a long time."

Co-author Lun Ma added: "Photodynamic therapy is limited to treat superficial diseases such as skin cancer because current photosensitizers cannot be activated using high energy irradiations that are able to deeply penetrate into tissues. … It may be a breakthrough to bring photodynamic therapy to deep cancer treatment."

- here's the UT-Arlington report
- and here's the abstract

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…